Galena Biopharma Inc., of San Ramon, Calif., said that five phase I trials in healthy volunteers and one phase II single arm, open label pilot study in patients with myeloproliferative neoplasms (MPN) found that GALE-401, its controlled release version of anagrelide, is well tolerated.